logoAiPathly

Aviceda Therapeutics

A

Overview

Aviceda Therapeutics is a private, clinical-stage biotechnology company based in Cambridge, Massachusetts. The company specializes in developing next-generation immunomodulators to address various diseases, with a particular focus on those involving the innate immune system and chronic, non-resolving inflammation.

Key Focus Areas

  • Glyco-Immune Therapeutics: Aviceda s proprietary Glyco-Code technology platform and High Affinity Ligands of Siglecs (HALOS™) nanotechnology are leveraged to modulate the innate immune response. This innovative approach targets glyco-immune checkpoints and exploits interactions between glycans and innate immune cells.

Therapeutic Pipeline

  1. Ophthalmology:
    • AVD-104: An intravitreal glycomimetic nanoparticle for geographic atrophy (GA) secondary to age-related macular degeneration. Currently in Phase 2b/3 clinical trials.
    • AVD-302: In development for diabetic retinopathy.
    • AVD-401: Targeting retinoblastoma.
  2. Other Indications:
    • AVD-601: Oncology
    • AVD-701: Neurology
    • AVD-801 and AVD-901: Fibrosis

Technology and Platforms

  1. Cell-Based High-Throughput Screening (HTS): Enables rapid screening, selection, and optimization of ligands with high affinity and specificity for innate immune cells.
  2. Nanoparticle Technology: Proprietary delivery system for therapeutics, exemplified by the glycan-coated nanoparticles in AVD-104.

Funding and Development

Aviceda recently secured $207.5 million in Series C financing to advance its lead program, AVD-104, into pivotal trials. This substantial funding was backed by prominent healthcare funds and investors, demonstrating strong confidence in the company s potential.

Leadership and Expertise

The company boasts a cross-disciplinary team of recognized scientists, clinicians, and drug developers. Following the Series C financing round, Aviceda expanded its board of directors with industry experts, further strengthening its leadership position. In conclusion, Aviceda Therapeutics is well-positioned to address a wide range of inflammatory, degenerative, and fibrotic diseases through its innovative glyco-immune therapeutics and advanced technology platforms. The company s robust pipeline, cutting-edge technology, and strong financial backing make it a notable player in the biotechnology industry.

Products & Solutions

Aviceda Therapeutics, a clinical-stage biotech company, focuses on developing novel glyco-immune therapeutics to modulate the innate immune system and address chronic non-resolving inflammation. Their key products and solutions include:

AVD-104

  • Lead clinical-stage ophthalmic candidate
  • Targets geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
  • Intravitreal glycomimetic nanoparticle with dual mechanism of action:
    1. Repolarizes overactivated macrophages to reparative state
    2. Inhibits complement cascade amplification
  • Currently in Phase 2/3 clinical trial (SIGLEC trial)
  • Shown positive safety and efficacy outcomes, including substantial slowing of GA lesion growth and functional improvement in patients

Other Ophthalmology Products

  • AVD-302: Targeted at diabetic retinopathy
  • AVD-401: Targeted at retinoblastoma
  • AVD-104: Potential applications beyond GA in other eye diseases

Products in Other Therapeutic Areas

  • AVD-601: Focused on oncology
  • AVD-701: Focused on neurology
  • AVD-801: Focused on fibrosis

Technology Platform

Aviceda utilizes the proprietary HALOS™ nanotechnology platform for developing glyco-immune therapeutics. This platform enables the creation of highly selective ligands with maximum affinity and specificity for target immune cells and diseases.

Clinical Trials and Funding

Aviceda has secured $207.5 million in Series C financing to advance its clinical trials, particularly for AVD-104, which is moving into pivotal Phase 3 testing. In summary, Aviceda Therapeutics leverages glycobiology and advanced nanotechnology to develop innovative treatments across multiple therapeutic areas, with a strong focus on ophthalmology and immune modulation.

Core Technology

Aviceda Therapeutics' core technology revolves around the development of glyco-immune therapeutics (GITs) using their proprietary HALOS™ (High-Affinity Ligands of Siglecs) platform.

Key Components of HALOS™ Technology

  1. Siglecs: Sialic-Acid binding Immunoglobulin Like Lectins
    • Present on the surface of all immune cells
    • Regulate immune response through interactions with glyco-binding ligands
  2. Sialic Acid Mimetics (SAMs):
    • Synthetic ligands designed for higher binding affinity to Siglecs than natural ligands
    • Enable precise modulation of immune response, engaging both innate and adaptive immune cells
  3. High-Affinity Ligands:
    • Synthesized through a proprietary high-throughput screening library
    • Enable development of multivalent ligands targeting various immune cells with high specificity and affinity

Mechanism of Action

  • Interaction between synthetic ligands and Siglecs activates an intracellular biochemical cascade
  • Similar to PD-1/PD-L1 checkpoint pathway, but extends modulation to a broader range of immune cells
  • Allows precise targeting and modification of immune cell behavior

Applications

  • Treats a wide range of immune-dysfunction conditions
  • Targets ocular and systemic degenerative, immunologic, and inflammatory diseases
  • Lead candidate AVD-104 focuses on geographic atrophy associated with age-related macular degeneration (AMD)
  • Shows promise in other areas such as cardiovascular diseases and congenital disorders

Delivery Method

  • Therapeutics delivered via biodegradable nanoparticles
  • Safely and effectively targets immune-inflammatory conditions
  • Allows for specific and profound modulation of innate immune response In summary, Aviceda's HALOS™ technology platform represents a novel approach to immune modulation, leveraging glycobiology and nanotechnology to develop targeted therapeutics for a wide range of diseases.

Industry Peers

Aviceda Therapeutics, a clinical-stage biotechnology company, operates within the ophthalmology and immunomodulation sectors, with a particular focus on treatments for geographic atrophy and other inflammatory diseases. The following companies represent Aviceda's industry peers:

Ophthalmology and Geographic Atrophy Competitors

  1. Iveric Bio: Developing Zimura (avacincaptad pegol)
  2. Alkeus Pharmaceuticals: Working on ALK-001
  3. Allegro Ophthalmics: Developing Risuteganib
  4. Stealth BioTherapeutics: Focused on Elamipretide
  5. Novartis: Developing PPY988 and GT005 (in collaboration with Gyroscope Therapeutics)
  6. Apellis Pharmaceuticals: Developing APL-2
  7. Ionis Pharmaceuticals: Working on IONIS-FB-LRx

Immunomodulation and Biotechnology Peers

  1. Annexon: Developing ANX007 for geographic atrophy and other inflammatory conditions
  2. Genentech: Focused on OpRegen for geographic atrophy and other ophthalmic indications
  3. NGM Biopharmaceuticals: Developing NGM621 for geographic atrophy
  4. Astellas Pharma: Working on ASP7317 for geographic atrophy
  5. Gyroscope Therapeutics: Collaborating with Novartis on GT005 for geographic atrophy These companies are all involved in the development of novel therapies for geographic atrophy and related ophthalmic conditions, making them significant competitors and peers to Aviceda Therapeutics in the industry. The competitive landscape highlights the growing interest and investment in addressing age-related macular degeneration and other ocular diseases, with various approaches and technologies being explored to improve patient outcomes.

More Companies

E

European Investment Bank

The European Investment Bank (EIB) is a cornerstone financial institution of the European Union, established in 1958 by the Treaty of Rome. As the world's largest multilateral lender and borrower, the EIB plays a crucial role in advancing EU policy objectives and fostering economic development. Key aspects of the EIB include: 1. Role and Objectives: - Support development of less-developed regions within the EU - Facilitate balanced development of the internal market - Mitigate climate change and promote environmental sustainability - Foster economic growth, innovation, and job creation 2. Structure: - Board of Governors: Comprises EU finance ministers, defining general lending policy - Board of Directors: Chaired by EIB President, approves lending and borrowing operations - Management Committee: Handles day-to-day operations 3. Funding and Operations: - Raises funds through international capital markets - Provides loans, guarantees, and technical assistance aligned with EU policy objectives - Lends about 90% within the EU, with the remainder supporting global development 4. Key Activities: - Climate and Environment: Major green finance provider, committed to €1 trillion in climate-related projects by 2030 - SME Support: Offers venture capital and risk finance through the European Investment Fund - Infrastructure and Development: Funds projects in less-developed regions and sectors - Crisis Response: Provides finance during crises like the 2008 financial crash and COVID-19 pandemic 5. Global Presence: - Active in over 140 countries through EIB Global - Supports EU development aid and cooperation policies worldwide 6. Additional Initiatives: - Part of the European Commission's Investment Plan for Europe - Works with EIF to improve SME access to finance and develop risk capital markets The EIB continues to be a vital institution in advancing EU goals, fostering economic development, and addressing global challenges such as climate change.

P

Perplexity

Perplexity AI is an advanced AI-powered search engine and information discovery tool that revolutionizes how users find, organize, and utilize information. Here's a comprehensive overview of its key features and capabilities: ### Core Functionality - **Intelligent Question Answering**: Perplexity leverages cutting-edge AI models, including GPT-4, Claude 3, and proprietary algorithms, to provide real-time answers by analyzing top-tier sources across the internet. - **Smart Summarization**: The platform distills complex information into clear, concise responses, often adopting a conversational tone for enhanced user engagement. ### Key Features - **Contextual Conversations**: Perplexity maintains context throughout user interactions, enabling seamless follow-up queries and a more natural dialogue experience. - **Source Transparency**: All responses include numbered footnotes linking to original sources, promoting information verifiability and further exploration. - **Pro Search**: This feature offers a guided AI search experience, allowing users to delve deeper into topics through iterative questioning. ### Advanced Capabilities - **Real-Time Information**: Daily web indexing ensures up-to-date information, including live updates for current events. - **Internal Knowledge Integration**: Pro and Enterprise users can search both web content and internal documents, including various file formats. - **Perplexity Spaces**: An AI-powered collaboration hub for creating customized knowledge spaces, combining web searches with personal file integration. - **Thread Organization**: Users can categorize searches by project or topic, with adjustable privacy settings. ### Additional Features - **File Interaction**: Seamless questioning and web searching within the platform, providing a unified project view. - **AI Image Generation**: Pro users can generate images using various AI tools. - **Financial Tools**: Basic stock price lookup and financial analysis capabilities. ### Accessibility and Plans - **Freemium Model**: Offers a free plan with GPT-3.5 and a Pro plan with advanced features and models. - **Cross-Platform Integration**: Available through mobile apps and browser extensions for versatile use. ### Recent Innovations - **Shopping Hub**: Launched in November 2024, providing product recommendations for shopping-related queries. - **Enterprise Solutions**: Enhanced offerings for businesses, including internal knowledge search and advanced AI model access. Perplexity AI stands out as a versatile, AI-driven platform that combines sophisticated search capabilities with collaborative features, making it a powerful tool for information discovery and knowledge management in the digital age.

A

Anthropic

Anthropic PBC is a U.S.-based artificial intelligence (AI) public-benefit startup founded in 2021 by former OpenAI employees. The company's mission is to research and develop safe, reliable AI systems that benefit humanity. Key aspects of Anthropic include: 1. Structure: Incorporated as a Delaware public-benefit corporation (PBC), balancing private and public interests. 2. Leadership: Founded by siblings Dario Amodei (CEO) and Daniela Amodei (President), along with other AI experts. 3. Funding: Secured significant investments, including $4 billion from Amazon and $2 billion from Google. 4. AI Models: Developed the Claude family of large language models, competing with ChatGPT and Gemini. 5. Constitutional AI: Employs a framework to align AI systems with human values, ensuring helpfulness, harmlessness, and honesty. 6. Research Focus: Investigates interpretability of machine learning systems, particularly transformer architectures. 7. Applications: Claude models are integrated into platforms like Latenode for various uses, including customer service and content creation. Anthropic's commitment to responsible AI development, emphasis on safety, and innovative approaches position it as a significant player in the AI industry.

A

Asian Development Bank

The Asian Development Bank (ADB) is a multilateral development finance institution dedicated to promoting economic growth, social progress, and poverty reduction in the Asia and Pacific region. Established on December 19, 1966, under Japan's leadership, the ADB is headquartered in Manila, Philippines, and comprises 67 members, including 48 regional and 19 non-regional countries. The ADB's primary mission is to foster economic growth and cooperation in the Asia-Pacific Region, aiming to build a prosperous, inclusive, resilient, and sustainable region while eradicating extreme poverty. The bank's operations align with the United Nations' Sustainable Development Goals (SDGs), focusing on key areas such as education, health, transport, energy, finance, and climate change. Financial Assistance and Services: - Loans: Both sovereign and private sector - Grants: For specific development projects - Technical Assistance: Enhancing member countries' capacities - Equity Investments: In private sector and public-private partnership projects - Cofinancing Operations: Mobilizing resources from various sources The ADB's operational structure includes the Board of Governors as its highest policy-making body, with powers delegated to the Board of Directors. Japan and the United States are the largest shareholders. Key Activities and Initiatives: - Policy dialogues and advisory services - Private sector development support - Public-private partnerships - Crisis response (e.g., COVID-19 pandemic support) As of 2020, the ADB reported an overall portfolio of US$116.5 billion and awarded 6,931 development contracts valued at US$10.3 billion. In 2021, the bank committed nearly US$13.5 billion to help its developing member countries address the impacts of the COVID-19 crisis. The ADB collaborates with other international financial institutions, such as the International Monetary Fund (IMF) and the World Bank, to achieve its development goals in the Asia-Pacific region.